This site is intended for Healthcare Professionals only.

Sanofi to buy Kadmon for $1.9bn, expanding transplant-drug portfolio

Date:

Share post:

Drug major Sanofi has agreed to buy US biopharmaceutical company Kadmon Holdings Inc. for $1.9 billion, expanding its transplant-drug portfolio.

Shareholders of Kadmon common stock will receive $9.50 per share in cash.

The Sanofi and Kadmon Boards of Directors unanimously approved the transaction under the merger agreement, marking the French drug maker’s third major acquisition this year.

Last month, the company agreed to acquire its messenger-RNA development partner Translate Bio Inc. for $3.2bn, and in April, it completed the purchase of Kymab Ltd., a maker of antibody treatments, for $1.1bn.

Kadmon’s acquisition is in line with Sanofi’s strategy to grow its General Medicines core assets, and it will immediately add Rezurock™(belumosudil) to its transplant portfolio.

“We are transforming and simplifying our General Medicines business and have shifted our focus on differentiated core assets in key markets,” said Olivier Charmeil, executive vice president General Medicines, Sanofi.

He added that Sanofi’s “existing scale, expertise, and relationships in transplant” can help in achieving the full potential of Rezurock.

Rezurock is a recently FDA-approved, first-in-class treatment for chronic graft-versus-host disease (cGVHD) for adult and pediatric patients 12 years and older who have failed at least two prior lines of systemic therapy.

Harlan Waksal, managing director, president and chief executive officer of Kadmon said with Sanofi’s global resources and expertise in innovative medicine, “Rezurock is now well positioned for global accessibility”.

Sanofi will work closely with regulatory authorities across different geographies to spread the belumosudil treatment. Kadmon is also developing Rezurock for the treatment of diffuse cutaneous systemic sclerosis.

Sanofi’s transplant business mainly consists of Thymoglobulin® (anti-thymocyte globulin), a polyclonal, anti-human thymocyte antibody preparation and Mozobil® (plerixafor), a hematopoietic stem cell mobilizer.

Kadmon’s pipeline includes drug candidates for immune and fibrotic diseases as well as immuno-oncology therapies.

Sanofi expects to complete the acquisition in the fourth quarter of 2021, and plans to fund the transaction with available cash resources.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

#SaveOurPharmacies: NPA distributes fair funding campaign posters, stickers

The National Pharmacy Association (NPA) is distributing new campaign materials to pharmacies across England this week to empower...

Lake District pharmacy grapples with medicine shortages amidst growing crisis

79% of pharmacists fear for patient health according to Community Pharmacy England report A Lake District pharmacy is grappling...

Common antibiotic for whooping cough treatment ‘completely out of stock’ – Dr. Leyla Hannbeck

Whooping cough caused five infant deaths in the first quarter of 2024, according to UKHSA Pharmacists in the UK...

Labour with Nuffield Health to aid thousands of NHS staff with joint pain return to work

Nurses accounted for 52,000 of sick days, doctors for 3,500, both up since 2019 as per the Labour...